<?xml version="1.0" encoding="UTF-8"?>
<record
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd"
    xmlns="http://www.loc.gov/MARC21/slim">

  <leader>27603cam a22005774a 4500</leader>
  <controlfield tag="003">OSt</controlfield>
  <controlfield tag="005">20240322151847.0</controlfield>
  <controlfield tag="006">m        d        </controlfield>
  <controlfield tag="007">co ugu||||||||</controlfield>
  <controlfield tag="008">060501t20072007moua     b    001 0 eng  </controlfield>
  <datafield tag="020" ind1=" " ind2=" ">
    <subfield code="a">1416025529</subfield>
  </datafield>
  <datafield tag="020" ind1=" " ind2=" ">
    <subfield code="a">9781416025528</subfield>
  </datafield>
  <datafield tag="040" ind1=" " ind2=" ">
    <subfield code="a">DNLM/DLC</subfield>
    <subfield code="b">eng</subfield>
    <subfield code="c">KAMPALA UNIVERSITY NURSING SCHOOL</subfield>
    <subfield code="d">KAMPALA UNIVERSITY NURSING SCHOOL</subfield>
    <subfield code="e">RDA</subfield>
  </datafield>
  <datafield tag="050" ind1="0" ind2="0">
    <subfield code="a">RM 301</subfield>
    <subfield code="b">.P457 2007</subfield>
  </datafield>
  <datafield tag="060" ind1="1" ind2="0">
    <subfield code="a">QV 4</subfield>
    <subfield code="b">L 523 2007</subfield>
  </datafield>
  <datafield tag="100" ind1="1" ind2=" ">
    <subfield code="a">Lehne, Richard A.,</subfield>
    <subfield code="d">1943-</subfield>
    <subfield code="e">author</subfield>
    <subfield code="9">3878</subfield>
  </datafield>
  <datafield tag="245" ind1="1" ind2="0">
    <subfield code="a">Pharmacology for nursing care /</subfield>
    <subfield code="c">Richard A. Lehne, </subfield>
  </datafield>
  <datafield tag="250" ind1=" " ind2=" ">
    <subfield code="a">6th ed</subfield>
  </datafield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="a">Canada:</subfield>
    <subfield code="b">Elsevier;</subfield>
    <subfield code="c">2007</subfield>
  </datafield>
  <datafield tag="300" ind1=" " ind2=" ">
    <subfield code="a">xxii, 1,354 p. :</subfield>
    <subfield code="b">col, ill ;</subfield>
    <subfield code="c">29 cm +</subfield>
    <subfield code="e">1 CD-ROM (4 3/4 in.)</subfield>
  </datafield>
  <datafield tag="504" ind1=" " ind2=" ">
    <subfield code="a">Includes bibliographical references and index</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2="0">
    <subfield code="g">[pt]. 1.</subfield>
    <subfield code="t">Introduction --</subfield>
    <subfield code="g">1.</subfield>
    <subfield code="t">Orientation to pharmacology --</subfield>
    <subfield code="t">Four basic terms --</subfield>
    <subfield code="t">Properties of an ideal drug --</subfield>
    <subfield code="t">The therapeutic objective --</subfield>
    <subfield code="t">Factors that determine the intensity of drug responses --</subfield>
    <subfield code="g">2.</subfield>
    <subfield code="t">Application of pharmacology in nursing practice --</subfield>
    <subfield code="t">Evolution of nursing responsibilities regarding drugs --</subfield>
    <subfield code="t">Application of pharmacology in patient care --</subfield>
    <subfield code="t">Application of pharmacology in patient education --</subfield>
    <subfield code="t">Application of the nursing process in drug therapy --</subfield>
    <subfield code="g">3.</subfield>
    <subfield code="t">Drug regulation, development, names, and information --</subfield>
    <subfield code="t">Landmark drug legislation --</subfield>
    <subfield code="t">New drug development --</subfield>
    <subfield code="t">Drug names --</subfield>
    <subfield code="t">Over-the-counter drugs --</subfield>
    <subfield code="t">Sources of drug information --</subfield>
    <subfield code="g">[pt]. 2.</subfield>
    <subfield code="t">Basic principles of pharmacology --</subfield>
    <subfield code="g">4.</subfield>
    <subfield code="t">Pharmacokinetics --</subfield>
    <subfield code="t">Application of pharmacokinetics in therapeutics --</subfield>
    <subfield code="t">A note to chemophobes --</subfield>
    <subfield code="t">Passage of drugs across membranes --</subfield>
    <subfield code="t">Absorption --</subfield>
    <subfield code="t">Distribution --</subfield>
    <subfield code="t">Metabolism--</subfield>
    <subfield code="t">Excretion --</subfield>
    <subfield code="t">Time course of drug responses --</subfield>
    <subfield code="g">5.</subfield>
    <subfield code="t">Pharmacodynamics --</subfield>
    <subfield code="t">Dose-response relationships --</subfield>
    <subfield code="t">Drug-receptor interactions --</subfield>
    <subfield code="t">Drug responses that do not involve receptors --</subfield>
    <subfield code="t">Interpatient variability in drug responses --</subfield>
    <subfield code="t">The therapeutic index --</subfield>
    <subfield code="g">6.</subfield>
    <subfield code="t">Drug interactions --</subfield>
    <subfield code="t">Drug-drug interactions --</subfield>
    <subfield code="t">Drug-food interactions --</subfield>
    <subfield code="t">Drug-herb interactions</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2="0">
    <subfield code="g">7.</subfield>
    <subfield code="t">Adverse drug reactions and medication errors --</subfield>
    <subfield code="t">Adverse drug reactions --</subfield>
    <subfield code="t">Medication errors --</subfield>
    <subfield code="g">8.</subfield>
    <subfield code="t">Individual variation in drug responses --</subfield>
    <subfield code="t">Body weight and composition --</subfield>
    <subfield code="t">Age --</subfield>
    <subfield code="t">Pathophysiology --</subfield>
    <subfield code="t">Tolerance --</subfield>
    <subfield code="t">Placebo effect --</subfield>
    <subfield code="t">Variability in absorption --</subfield>
    <subfield code="t">Genetics --</subfield>
    <subfield code="t">Gender --</subfield>
    <subfield code="t">Race --</subfield>
    <subfield code="t">Failure to take medicine as prescribed --</subfield>
    <subfield code="t">Drug interactions --</subfield>
    <subfield code="t">Diet</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2="0">
    <subfield code="g">[pt]. 3.</subfield>
    <subfield code="t">Drug therapy across the lifespan --</subfield>
    <subfield code="g">9.</subfield>
    <subfield code="t">Drug therapy during pregnancy and breast-feeding --</subfield>
    <subfield code="t">Drug therapy during pregnancy : basic considerations --</subfield>
    <subfield code="t">Drug therapy during pregnancy : teratogenesis --</subfield>
    <subfield code="t">Drug therapy during breast-feeding --</subfield>
    <subfield code="g">10.</subfield>
    <subfield code="t">Drug therapy in pediatric patients --</subfield>
    <subfield code="t">Pharmacokinetics : neonates and infants --</subfield>
    <subfield code="t">Pharmacokinetics : children 1 year and older --</subfield>
    <subfield code="t">Adverse drug reactions --</subfield>
    <subfield code="t">Dosage determination --</subfield>
    <subfield code="t">Promoting adherence --</subfield>
    <subfield code="g">11.</subfield>
    <subfield code="t">Drug therapy in geriatric patients --</subfield>
    <subfield code="t">Pharmacokinetic changes in the elderly --</subfield>
    <subfield code="t">Pharmacodynamic changes in the elderly --</subfield>
    <subfield code="t">Adverse drug reactions and drug interactions --</subfield>
    <subfield code="t">Promoting adherence --</subfield>
    <subfield code="g">[pt]. 4.</subfield>
    <subfield code="t">Peripheral nervous system drugs --</subfield>
    <subfield code="t">Introduction --</subfield>
    <subfield code="g">12.</subfield>
    <subfield code="t">Basic principles of neuropharmacology --</subfield>
    <subfield code="t">How neurons regulate physiologic processes --</subfield>
    <subfield code="t">Basic mechanisms by which neuropharmacologic agents act --</subfield>
    <subfield code="g">13.</subfield>
    <subfield code="t">Physiology of the peripheral nervous system --</subfield>
    <subfield code="t">Divisions of the nervous system --</subfield>
    <subfield code="t">Overview of autonomic nervous system functions --</subfield>
    <subfield code="t">Basic mechanisms by which the autonomic nervous system regulates physiologic processes --</subfield>
    <subfield code="t">Anatomic considerations --</subfield>
    <subfield code="t">Introduction to transmitters of the peripheral nervous system --</subfield>
    <subfield code="t">Introduction to receptors of the peripheral nervous system --</subfield>
    <subfield code="t">Exploring the concept of receptor subtypes --</subfield>
    <subfield code="t">Locations of receptor subtypes --</subfield>
    <subfield code="t">Functions of cholinergic and adrenergic receptor subtypes --</subfield>
    <subfield code="t">receptor specificity of the adrenergic receptor subtypes --</subfield>
    <subfield code="t">Receptor specificity of the adrenergic transmitters --</subfield>
    <subfield code="t">Transmitter life cycles</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2="0">
    <subfield code="t">Cholinergic drugs --</subfield>
    <subfield code="g">14.</subfield>
    <subfield code="t">Muscarinic agonists and antagonists --</subfield>
    <subfield code="t">Muscarinic agonists --</subfield>
    <subfield code="t">Muscarinic antagonists (anticholinergic drugs) --</subfield>
    <subfield code="g">15.</subfield>
    <subfield code="t">Cholinesterase inhibitors and their use in myasthenia gravis --</subfield>
    <subfield code="t">Reversible cholinesterase inhibitors --</subfield>
    <subfield code="t">"Irreversible" cholinesterase inhibitors --</subfield>
    <subfield code="t">Myasthenia gravis --</subfield>
    <subfield code="g">16.</subfield>
    <subfield code="t">Drugs that block nicotinic cholinergic transmission : neuromuscular blocking agents and ganglionic blocking agents --</subfield>
    <subfield code="t">Neuromuscular blocking agents --</subfield>
    <subfield code="t">Ganglionic blocking agents --</subfield>
    <subfield code="t">Adrenergic drugs --</subfield>
    <subfield code="g">17.</subfield>
    <subfield code="t">Adrenergic agonists --</subfield>
    <subfield code="t">Mechanisms of adrenergic receptor activation --</subfield>
    <subfield code="t">Overview of the adrenergic agonists --</subfield>
    <subfield code="t">Therapeutic applications and adverse effects of adrenergic receptor activation --</subfield>
    <subfield code="t">Properties of representative adrenergic agonists --</subfield>
    <subfield code="t">Discussion of adrenergic agonists in other chapters --</subfield>
    <subfield code="g">18.</subfield>
    <subfield code="t">Adrenergic antagonists --</subfield>
    <subfield code="t">Alpha-adrenergic antagonists 1 : therapeutic and adverse responses to alpha blockade --</subfield>
    <subfield code="t">Alpha-adrenergic antagonists 2 : properties of individual alpha blockers --</subfield>
    <subfield code="g">19.</subfield>
    <subfield code="t">Indirect-acting antiadrenergic agents --</subfield>
    <subfield code="t">Adrenergic neuron-blocking agents --</subfield>
    <subfield code="t">Centrally acting alpha&#x2082; agonists</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2="0">
    <subfield code="g">[pt]. 5.</subfield>
    <subfield code="t">Central nervous system drugs --</subfield>
    <subfield code="g">20.</subfield>
    <subfield code="t">Introduction to central nervous system pharmacology --</subfield>
    <subfield code="t">Transmitters of the CNS --</subfield>
    <subfield code="t">The blood-brain barrier --</subfield>
    <subfield code="t">How do CNS drugs produce therapeutic effects? --</subfield>
    <subfield code="t">Adaptation of the CNS to prolonged drug exposure --</subfield>
    <subfield code="t">Development of new psychotherapeutic drugs --</subfield>
    <subfield code="t">Approaching the study of CNS drugs --</subfield>
    <subfield code="t">Drugs for neurodegenerative disorders --</subfield>
    <subfield code="g">21.</subfield>
    <subfield code="t">Drugs for Parkinson's disease --</subfield>
    <subfield code="t">Pathophysiology of Parkinson's disease --</subfield>
    <subfield code="t">Overview of drug therapy --</subfield>
    <subfield code="t">Pharmacology of the drugs used for Parkinson's disease --</subfield>
    <subfield code="g">22.</subfield>
    <subfield code="t">Alzheimer's disease --</subfield>
    <subfield code="t">Pathophysiology of Alzheimer's disease --</subfield>
    <subfield code="t">Risk factors, symptoms, and diagnosis --</subfield>
    <subfield code="t">Drug therapy --</subfield>
    <subfield code="g">23.</subfield>
    <subfield code="t">Drugs for multiple sclerosis --</subfield>
    <subfield code="t">Overview of MS and its treatment --</subfield>
    <subfield code="t">Disease modifying drugs 1 : immunomodulators --</subfield>
    <subfield code="t">Disease modifying drugs 2 : immunosuppressants --</subfield>
    <subfield code="t">Drugs used to manage MS symptoms --</subfield>
    <subfield code="t">Neurologic drugs --</subfield>
    <subfield code="g">24.</subfield>
    <subfield code="t">Drugs for epilepsy --</subfield>
    <subfield code="t">Seizure generation--</subfield>
    <subfield code="t">Types of seizures --</subfield>
    <subfield code="t">How antiepileptic drugs work --</subfield>
    <subfield code="t">Basic therapeutic considerations --</subfield>
    <subfield code="t">Classification of antiepileptic drugs --</subfield>
    <subfield code="t">Traditional antiepileptic drugs --</subfield>
    <subfield code="t">Newer antiepileptic drugs --</subfield>
    <subfield code="t">Management of epilepsy during pregnancy --</subfield>
    <subfield code="t">Management of generalized convulsive status epilepticus</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2="0">
    <subfield code="g">25.</subfield>
    <subfield code="t">Drugs for muscle spasm and spasticity --</subfield>
    <subfield code="t">Seizure generation --</subfield>
    <subfield code="t">Types of seizures --</subfield>
    <subfield code="t">How antiepileptic drugs work --</subfield>
    <subfield code="t">Basic therapeutic considerations--</subfield>
    <subfield code="t">Classification of antiepileptic drugs --</subfield>
    <subfield code="t">Traditional antiepileptic drugs --</subfield>
    <subfield code="t">Newer antiepileptic drugs --</subfield>
    <subfield code="t">Management of epilepsy during pregnancy --</subfield>
    <subfield code="t">Management of generalized convulsive status epilepticus --</subfield>
    <subfield code="t">Drugs for pain --</subfield>
    <subfield code="t">Drug therapy of muscle spasm : centrally acting muscle relaxants --</subfield>
    <subfield code="t">Drugs for spasticity --</subfield>
    <subfield code="g">26.</subfield>
    <subfield code="t">Local anesthetics --</subfield>
    <subfield code="t">Basic pharmacology of the local anesthetics --</subfield>
    <subfield code="t">Properties of individual local anesthetics --</subfield>
    <subfield code="t">Clinical use of local anesthetics --</subfield>
    <subfield code="g">27.</subfield>
    <subfield code="t">General anesthetics --</subfield>
    <subfield code="t">Basic pharmacology of the inhalation anesthetics --</subfield>
    <subfield code="t">Properties of individual inhalation anesthetics --</subfield>
    <subfield code="t">Intravenous anesthetics --</subfield>
    <subfield code="g">28.</subfield>
    <subfield code="t">Opioid (narcotic) analgesics, opioid antagonists, and nonopioid centrally acting analgesics --Introduction to the opioids --</subfield>
    <subfield code="t">Basic pharmacology of the opioids --</subfield>
    <subfield code="t">Clinical use of opioids --</subfield>
    <subfield code="t">Opioid antagonists --</subfield>
    <subfield code="t">Nonopioid centrally acting analgesics --</subfield>
    <subfield code="g">29.</subfield>
    <subfield code="t">Pain management in patients with cancer --</subfield>
    <subfield code="t">Pathophysiology of pain --</subfield>
    <subfield code="t">Management strategy --</subfield>
    <subfield code="t">Assessment and ongoing evaluation --</subfield>
    <subfield code="t">Drug therapy --</subfield>
    <subfield code="t">Nondrug therapy --</subfield>
    <subfield code="t">Pain management in special populations --</subfield>
    <subfield code="t">patient education --</subfield>
    <subfield code="t">JCAHO pain management standards</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2="0">
    <subfield code="g">30.</subfield>
    <subfield code="t">Drugs for headache --</subfield>
    <subfield code="t">Migraine headache 1 : characteristics and overview of treatment --</subfield>
    <subfield code="t">Migraine headache 2 : abortive therapy --</subfield>
    <subfield code="t">Migraine headache 3 : preventive therapy --</subfield>
    <subfield code="t">Cluster headaches --</subfield>
    <subfield code="t">Tension[type headache --</subfield>
    <subfield code="t">Psychotherapeutic drugs --</subfield>
    <subfield code="g">31.</subfield>
    <subfield code="t">Antipsychotic agents and their use in schizophrenia --</subfield>
    <subfield code="t">Schizophrenia : clinical presentation and etiology--</subfield>
    <subfield code="t">Conventional antipsychotic agents 1 : group properties --</subfield>
    <subfield code="t">Conventional antipsychotic agents 2 : properties of individual agents --</subfield>
    <subfield code="t">Atypical antipsychotic agents --</subfield>
    <subfield code="t">Management of schizophrenia --</subfield>
    <subfield code="g">32.</subfield>
    <subfield code="t">Antidepressants --</subfield>
    <subfield code="t">Major depression : clinical features, pathogenesis, and treatment modalities --</subfield>
    <subfield code="t">Suicide risk with antidepressant drugs --</subfield>
    <subfield code="t">Tricyclic antidepressants --</subfield>
    <subfield code="t">Selective serotonin reuptake inhibitors (SSRIs) --</subfield>
    <subfield code="t">Serotonin/norepinephrine reuptake inhibitors (S/NRIs) --</subfield>
    <subfield code="t">Monoamine oxidase inhibitors (MAOIs) --</subfield>
    <subfield code="t">Atypical antidepressants --</subfield>
    <subfield code="t">Electroconvulsive therapy --</subfield>
    <subfield code="t">Vagus nerve stimulation --</subfield>
    <subfield code="g">33.</subfield>
    <subfield code="t">Drugs for bipolar disorder --</subfield>
    <subfield code="t">Characteristics of bipolar disorder --</subfield>
    <subfield code="t">Treatment of bipolar disorder --</subfield>
    <subfield code="t">Mood-stabilizing drugs --</subfield>
    <subfield code="t">Antipsychotic drugs --</subfield>
    <subfield code="g">34.</subfield>
    <subfield code="t">Sedative-hypnotic drugs --</subfield>
    <subfield code="t">Benzodiazepines --</subfield>
    <subfield code="t">Benzodiazepine-like drugs --</subfield>
    <subfield code="t">Ramelteon : a melatonin agonist --</subfield>
    <subfield code="t">Barbiturates --</subfield>
    <subfield code="t">Miscellaneous sedative-hypnotics --</subfield>
    <subfield code="t">Management of transient insomnia</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2="0">
    <subfield code="g">35.</subfield>
    <subfield code="t">Management of anxiety disorders --</subfield>
    <subfield code="t">Generalization anxiety disorder --</subfield>
    <subfield code="t">Panic disorder --</subfield>
    <subfield code="t">Obsessive-compulsive disorder --</subfield>
    <subfield code="t">Social anxiety disorder (social phobia) --</subfield>
    <subfield code="t">Post-traumatic stress disorder --</subfield>
    <subfield code="g">36.</subfield>
    <subfield code="t">Central nervous system stimulants and attention-deficit/hyperactivity disorder --</subfield>
    <subfield code="t">Amphetamines --</subfield>
    <subfield code="t">Methylphenidate and dexmethylphenidate --</subfield>
    <subfield code="t">Methylxanthines --</subfield>
    <subfield code="t">Miscellaneous CNS stimulants --</subfield>
    <subfield code="t">Attention-deficit/hyperactivity disorder --</subfield>
    <subfield code="t">Drug abuse --</subfield>
    <subfield code="g">37.</subfield>
    <subfield code="t">Drug abuse 1 : basic considerations --</subfield>
    <subfield code="t">Definitions --</subfield>
    <subfield code="t">Diagnostic criteria for substance abuse and substance dependence --</subfield>
    <subfield code="t">Factors that contribute to drug abuse --</subfield>
    <subfield code="t">neurobiology of addiction --</subfield>
    <subfield code="t">Principles of addiction treatment --</subfield>
    <subfield code="t">The Controlled Substance Act --</subfield>
    <subfield code="g">38.</subfield>
    <subfield code="t">Drug abuse 2 : alcohol --</subfield>
    <subfield code="t">Basic pharmacology of alcohol --</subfield>
    <subfield code="t">Alcohol abuse --</subfield>
    <subfield code="t">Drugs employed in alcohol abuse treatment --</subfield>
    <subfield code="g">39.</subfield>
    <subfield code="t">Drug abuse 3 : major drugs of abuse (other than alcohol) --</subfield>
    <subfield code="t">Heroin and other opioids --</subfield>
    <subfield code="t">General CNS depressants --</subfield>
    <subfield code="t">Psychostimulants --</subfield>
    <subfield code="t">Marijuana and related preparations --</subfield>
    <subfield code="t">Psychedelics --</subfield>
    <subfield code="t">3, 4-methylenedioxymethamphetamine (MDMA, Ecstasy) --</subfield>
    <subfield code="t">Phencyclidine --</subfield>
    <subfield code="t">Inhalants --</subfield>
    <subfield code="t">Nicotine and smoking --</subfield>
    <subfield code="t">Anabolic steroids</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2="0">
    <subfield code="g">[pt]. 6.</subfield>
    <subfield code="t">Drugs that affect fluid and electrolyte balance --</subfield>
    <subfield code="g">40.</subfield>
    <subfield code="t">Diuretics --</subfield>
    <subfield code="t">Review of renal anatomy and physiology --</subfield>
    <subfield code="t">Introduction to diuretics --</subfield>
    <subfield code="t">High-ceiling (loop) diuretics --</subfield>
    <subfield code="t">Thiazides and related diuretics --</subfield>
    <subfield code="t">Thiazides and related diuretics --</subfield>
    <subfield code="t">Potassium-sparing diuretics --</subfield>
    <subfield code="t">Osmotic diuretics --</subfield>
    <subfield code="g">41.</subfield>
    <subfield code="t">Agents affecting the volume and ion content of body fluids --</subfield>
    <subfield code="t">Disorders of fluid volume and osmolality --</subfield>
    <subfield code="t">Acid-base disturbances --</subfield>
    <subfield code="t">Potassium imbalances --</subfield>
    <subfield code="t">Magnesium imbalances --</subfield>
    <subfield code="g">[pt]. 7.</subfield>
    <subfield code="t">Drugs that affect the heart, blood vessels, and blood --</subfield>
    <subfield code="g">42.</subfield>
    <subfield code="t">Review of hemodynamics --</subfield>
    <subfield code="t">Overview of the circulatory system --</subfield>
    <subfield code="t">Regulation of cardiac output --</subfield>
    <subfield code="t">Regulation of arterial pressure --</subfield>
    <subfield code="g">43.</subfield>
    <subfield code="t">Drugs acting on the renin-angiotensin-aldosterone system --</subfield>
    <subfield code="t">Physiology of the renin-angiotensin-aldosterone system --</subfield>
    <subfield code="t">Angiotensin-converting enzyme inhibitors --</subfield>
    <subfield code="t">Angiotensin 2 receptor blockers --</subfield>
    <subfield code="t">Aldosterone antagonists --</subfield>
    <subfield code="g">44.</subfield>
    <subfield code="t">Calcium channel blockers --</subfield>
    <subfield code="t">Calcium channels : physiologic functions and consequences of blockade --</subfield>
    <subfield code="t">Calcium channel blockers : classification and sites of action --</subfield>
    <subfield code="t">Verapamil and diltiazem : agents that act on vascular smooth muscle and the heart --</subfield>
    <subfield code="t">Dihydropyridines : agents that act mainly on vascular smooth muscle</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2="0">
    <subfield code="g">45.</subfield>
    <subfield code="t">Vasodilators --</subfield>
    <subfield code="t">Basic concepts invasodilator pharmacology --</subfield>
    <subfield code="t">Pharmacology of individual vasodilators --</subfield>
    <subfield code="g">46.</subfield>
    <subfield code="t">Drugs for hypertension --</subfield>
    <subfield code="t">Classification of blood pressure --</subfield>
    <subfield code="t">Types of hypertension --</subfield>
    <subfield code="t">Consequences of hypertension --</subfield>
    <subfield code="t">Management of chronic hypertension 1 : basic considerations --</subfield>
    <subfield code="t">Management of chronic hypertension 2 : lifestyle modifications --</subfield>
    <subfield code="t">Management of chronic hypertension 3 : drug therapy --</subfield>
    <subfield code="t">Drugs for hypertensive emergencies --</subfield>
    <subfield code="t">Drugs for hypertensive disorders of pregnancy --</subfield>
    <subfield code="g">47.</subfield>
    <subfield code="t">Drugs for heart failure --</subfield>
    <subfield code="t">Pathophysiology of heart failure --</subfield>
    <subfield code="t">Overview of drugs used to treat heart failure --</subfield>
    <subfield code="t">Cardiac (digitalis) glycosides --</subfield>
    <subfield code="t">Management of heart failure --</subfield>
    <subfield code="g">48.</subfield>
    <subfield code="t">Antidysrhythmic drugs --</subfield>
    <subfield code="t">Electrical properties of the heart --</subfield>
    <subfield code="t">Generation of dysrhythmias --</subfield>
    <subfield code="t">Classification of antidysrhythmic drugs --</subfield>
    <subfield code="t">Prodysrhythmic effects of antidysrhythmic drugs --</subfield>
    <subfield code="t">Overview of common dysrhythmias and their treatment --</subfield>
    <subfield code="t">Class 1 : sodium channel blockers --</subfield>
    <subfield code="t">Class 2 : beta blockers --</subfield>
    <subfield code="t">Class 3 : potassium channel blockers (drugs that delay repolarization) --</subfield>
    <subfield code="t">Class 4 : calcium channel blockers --</subfield>
    <subfield code="t">Other antidysrhythmic drugs --</subfield>
    <subfield code="t">Principles of antidysrhythmic drug therapy --</subfield>
    <subfield code="t">Nondrug treatment of dysrhythmias</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2="0">
    <subfield code="g">49.</subfield>
    <subfield code="t">Prophylaxis of coronary heart disease : drugs that lower LDL cholesterol levels --</subfield>
    <subfield code="t">Cholesterol --</subfield>
    <subfield code="t">Plasma lipoproteins --</subfield>
    <subfield code="t">Role of LDL cholesterol in atherosclerosis --</subfield>
    <subfield code="t">Detection, evaluation, and treatment of high cholesterol : recommendations from ATP 3 --</subfield>
    <subfield code="t">Drugs and other products used to alter plasma lipid levels --</subfield>
    <subfield code="g">50.</subfield>
    <subfield code="t">Drugs for angina pectoris --</subfield>
    <subfield code="t">Determinants of cardiac oxygen demand and oxygen supply --</subfield>
    <subfield code="t">Angina pectoris : pathophysiology and treatment strategy --</subfield>
    <subfield code="t">Organic nitrates --</subfield>
    <subfield code="t">Beta blockers --</subfield>
    <subfield code="t">Calcium channel blockers --</subfield>
    <subfield code="t">Revascularization therapy : CABG and PCI --</subfield>
    <subfield code="t">Summary of treatment measures --</subfield>
    <subfield code="g">51.</subfield>
    <subfield code="t">Anticoagulant, antiplatelet, and thrombolytic drugs --</subfield>
    <subfield code="t">Physiology and pathophysiology of coagulation --</subfield>
    <subfield code="t">Overview of drugs used to treat thromboembolic disorders --</subfield>
    <subfield code="t">Parenteral anticoagulants 1 : heparin and related drugs --</subfield>
    <subfield code="t">Parenteral anticoagulants 2 : direct thrombin inhibitors --</subfield>
    <subfield code="t">Warfarin, and oral anticoagulant --</subfield>
    <subfield code="t">Antiplatelet drugs --</subfield>
    <subfield code="t">Thrombolytic drugs --</subfield>
    <subfield code="g">52.</subfield>
    <subfield code="t">Management of ST-elevation myocardial infarction --</subfield>
    <subfield code="t">Pathophysiology of STEMI --</subfield>
    <subfield code="t">Diagnosis of STEMI --</subfield>
    <subfield code="t">Management of STEMI --</subfield>
    <subfield code="t">Complications of STEMI --</subfield>
    <subfield code="t">Secondary prevention of STEMI --</subfield>
    <subfield code="g">53.</subfield>
    <subfield code="t">Drugs for hemophilia --</subfield>
    <subfield code="t">Basic considerations --</subfield>
    <subfield code="t">Preparations used to treat hemophilia --</subfield>
    <subfield code="g">53.</subfield>
    <subfield code="t">Drugs for deficiency anemias --</subfield>
    <subfield code="t">Red blood cell development --</subfield>
    <subfield code="t">Iron deficiency --</subfield>
    <subfield code="t">Vitamin B&#x2081;&#x2082; deficiency --</subfield>
    <subfield code="t">Folic acid defficiency --</subfield>
    <subfield code="g">55.</subfield>
    <subfield code="t">Hematopoietic growth factors --</subfield>
    <subfield code="t">Erythropoietic growth factors --</subfield>
    <subfield code="t">Luekopoietic growth factors --</subfield>
    <subfield code="t">Thrombopoietic growth factor</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2="0">
    <subfield code="g">[pt]. 8.</subfield>
    <subfield code="t">Drugs for endocrine disorders --</subfield>
    <subfield code="g">56.</subfield>
    <subfield code="t">Drugs for diabetes mellitus --</subfield>
    <subfield code="t">Diabetes mellitus : overview of the disease and its treatment --</subfield>
    <subfield code="t">Insulin 1 : physiology--</subfield>
    <subfield code="t">Insulin 2 : preparations and administration --</subfield>
    <subfield code="t">Insulin 3 : therapeutic use --</subfield>
    <subfield code="t">Oral hypoglycemics for type 2 diabetes --</subfield>
    <subfield code="t">New injectable drugs for diabetes --</subfield>
    <subfield code="t">Diabetic ketoacidosis --</subfield>
    <subfield code="t">Glucagon for insulin overdose --</subfield>
    <subfield code="g">57.</subfield>
    <subfield code="t">Drugs for thyroid disorders --</subfield>
    <subfield code="t">Thyroid physiology --</subfield>
    <subfield code="t">Thyroid function tests --</subfield>
    <subfield code="t">Thyroid pathophysiology --</subfield>
    <subfield code="t">Thyroid hormone preparations for hypothyroidism --</subfield>
    <subfield code="t">Drugs for hyperthyroidism --</subfield>
    <subfield code="g">58.</subfield>
    <subfield code="t">Drugs related to hypothalamic and pituitary function --</subfield>
    <subfield code="t">Overview of hypothalamic and pituitary endocrinology --</subfield>
    <subfield code="t">Growth hormone --</subfield>
    <subfield code="t">Prolactin --</subfield>
    <subfield code="t">Thyrotropin --</subfield>
    <subfield code="t">Corticotropin --</subfield>
    <subfield code="t">Gonadotropins --</subfield>
    <subfield code="t">Antidiuretic hormone --</subfield>
    <subfield code="t">Oxytoxin --</subfield>
    <subfield code="t">Drugs related to hypothalamic function --</subfield>
    <subfield code="g">59.</subfield>
    <subfield code="t">Drugs for disorders of the adrenal cortex --</subfield>
    <subfield code="t">Physiology of the adrenocortical hormones --</subfield>
    <subfield code="t">Pathophysiology of the adrenocortical hormones --</subfield>
    <subfield code="t">Agents for replacement therapy in adrenocortical insufficiency --</subfield>
    <subfield code="t">Agents for diagnostic testing of adrenocortical function --</subfield>
    <subfield code="t">Inhibitors of corticosteroid synthesis</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2="0">
    <subfield code="g">[pt]. 9.</subfield>
    <subfield code="t">Women's health --</subfield>
    <subfield code="g">60.</subfield>
    <subfield code="t">Estrogens and progestins : basic pharmacology and noncontraceptive applications --</subfield>
    <subfield code="t">The menstrual cycle --</subfield>
    <subfield code="t">Estrogens --</subfield>
    <subfield code="t">Selective estrogen receptor modulators (SERMs) --</subfield>
    <subfield code="t">Progestins --</subfield>
    <subfield code="t">Menopausal hormone therapy --</subfield>
    <subfield code="g">61.</subfield>
    <subfield code="t">Birth control --</subfield>
    <subfield code="t">Effectiveness and safety of birth control methods --</subfield>
    <subfield code="t">Selecting a birth control method --</subfield>
    <subfield code="t">Oral contraceptives --</subfield>
    <subfield code="t">Combination contraceptives with novel delivery systems --</subfield>
    <subfield code="t">Long-acting contraceptives --</subfield>
    <subfield code="t">Spermicides --</subfield>
    <subfield code="t">Barrier devices --</subfield>
    <subfield code="t">Drugs for medical abortion --</subfield>
    <subfield code="g">62.</subfield>
    <subfield code="t">Drug therapy of infertility --</subfield>
    <subfield code="t">Infertility : causes and treatment strategies --</subfield>
    <subfield code="t">Drugs used to treat female infertility --</subfield>
    <subfield code="g">63.</subfield>
    <subfield code="t">Drugs that affect uterine function --</subfield>
    <subfield code="t">Uterine relaxants (tocolytics) and their use in preterm labor --</subfield>
    <subfield code="t">Uterine stimulants (oxytocicis) --</subfield>
    <subfield code="t">Drugs used to promote cervical ripening --</subfield>
    <subfield code="g">[pt]. 10.</subfield>
    <subfield code="t">Men's health --</subfield>
    <subfield code="g">64.</subfield>
    <subfield code="t">Androgens --</subfield>
    <subfield code="t">Testosterone --</subfield>
    <subfield code="t">Clinical pharmacology of the androgens --</subfield>
    <subfield code="t">Androgen (anabolic steroid) abuse by athletes --</subfield>
    <subfield code="g">65.</subfield>
    <subfield code="t">Drugs for erectile dysfunction and benign prostatic hyperplasia --</subfield>
    <subfield code="t">Erectile dysfunction --</subfield>
    <subfield code="t">Benign prostatic hyperplasia</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2="0">
    <subfield code="g">[pt.] 11.</subfield>
    <subfield code="t">Anti-inflammartory, antiallergic, and immunologic drugs --</subfield>
    <subfield code="g">66.</subfield>
    <subfield code="t">Review of the immune system --</subfield>
    <subfield code="t">Introduction to the immune system --</subfield>
    <subfield code="t">Antibody-mediated (humoral) immunity --</subfield>
    <subfield code="t">Cell-mediated immunity --</subfield>
    <subfield code="g">67.</subfield>
    <subfield code="t">Childhood immunization --</subfield>
    <subfield code="t">General considerations --</subfield>
    <subfield code="t">Target diseases --</subfield>
    <subfield code="t">Specific vaccines and toxoids --</subfield>
    <subfield code="g">68.</subfield>
    <subfield code="t">Immunosuppressants --</subfield>
    <subfield code="t">Calcineurin inhibitors --</subfield>
    <subfield code="t">Sirlimus --</subfield>
    <subfield code="t">Glucocorticoids --</subfield>
    <subfield code="t">Cytotoxic drugs --</subfield>
    <subfield code="t">Antibodies --</subfield>
    <subfield code="g">69.</subfield>
    <subfield code="t">Antihistamines --</subfield>
    <subfield code="t">Histamine --</subfield>
    <subfield code="t">The two types of antihistamines : H&#x2081; antagonists and H&#x2082; antagonists --</subfield>
    <subfield code="t">H&#x2081; antagonists 1 : basic pharmacology --</subfield>
    <subfield code="t">H&#x2081; antagonists 2 : preparations --</subfield>
    <subfield code="g">70.</subfield>
    <subfield code="t">Cyclooxygenase inhibitors : nonsteroidal anti-inflammatory drugs and acetaminophen --</subfield>
    <subfield code="t">Mechanism of action --</subfield>
    <subfield code="t">Classificationod cyclooxygenase inhibitors --</subfield>
    <subfield code="t">First-generation NSAIDs --</subfield>
    <subfield code="t">Second-generation NSAIDs (COX-2 inhibitors, coxibs) --</subfield>
    <subfield code="t">Acetaminophen --</subfield>
    <subfield code="g">71.</subfield>
    <subfield code="t">Glucocorticoids in nonendocrine diseases --</subfield>
    <subfield code="t">Review of glucocorticoid physiology --</subfield>
    <subfield code="t">Pharmacology of the glucocorticoids --</subfield>
    <subfield code="g">[pt]. 12.</subfield>
    <subfield code="t">Drugs for bone and joint disorders --</subfield>
    <subfield code="g">72.</subfield>
    <subfield code="t">Drug therapy of rheumatoid arthritis and gout --</subfield>
    <subfield code="t">Drug therapy of rheumatoid arthritis --</subfield>
    <subfield code="t">Drug therapy of gout --</subfield>
    <subfield code="g">73.</subfield>
    <subfield code="t">Drugs affecting calcium levels and bone mineralization --</subfield>
    <subfield code="t">Calcium physiology --</subfield>
    <subfield code="t">Calcium-related pathophysiology--</subfield>
    <subfield code="t">Drugs for disorders involving calcium --</subfield>
    <subfield code="t">Osteoporosis</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2="0">
    <subfield code="g">[pt]. 13.</subfield>
    <subfield code="t">Respiratory tract drugs --</subfield>
    <subfield code="g">74.</subfield>
    <subfield code="t">Drugs for asthma --</subfield>
    <subfield code="t">Pathophysiology of asthma --</subfield>
    <subfield code="t">Overview of drugs for asthma --</subfield>
    <subfield code="t">Administration of drugs by inhalation --</subfield>
    <subfield code="t">Beta&#x2082;-adrenergic agonists --</subfield>
    <subfield code="t">Glucocorticoids --</subfield>
    <subfield code="t">Glucocorticoid/Beta&#x2082; agonist combination --</subfield>
    <subfield code="t">Cromolyn --</subfield>
    <subfield code="t">Nedocromil --</subfield>
    <subfield code="t">Methylxanthines --</subfield>
    <subfield code="t">Anticholinergic drugs --</subfield>
    <subfield code="t">Leukotriene modifiers --</subfield>
    <subfield code="t">Omalizumab --</subfield>
    <subfield code="t">Management of asthma --</subfield>
    <subfield code="g">75.</subfield>
    <subfield code="t">Drugs for allergic rhinitis, cough, and colds --</subfield>
    <subfield code="t">Drugs for allergic rhinitis --</subfield>
    <subfield code="t">Drugs for cough --</subfield>
    <subfield code="t">Cold remedies : combination preparations --</subfield>
    <subfield code="g">[pt]. 14.</subfield>
    <subfield code="t">Gastrointestinal drugs --</subfield>
    <subfield code="g">76.</subfield>
    <subfield code="t">Drugs for peptic ulcer disease --</subfield>
    <subfield code="g">77.</subfield>
    <subfield code="t">Laxatives --</subfield>
    <subfield code="g">78.</subfield>
    <subfield code="t">Other gastrointestinal drugs --</subfield>
    <subfield code="t">Antiemetics --</subfield>
    <subfield code="t">Drugs for motion sickness --</subfield>
    <subfield code="t">Antidiarrheal agents --</subfield>
    <subfield code="t">Drugs for irritable bowel syndrome --</subfield>
    <subfield code="t">Drugs for inflammatory bowel disease --</subfield>
    <subfield code="t">Prokinetic agents --</subfield>
    <subfield code="t">Palifermin --</subfield>
    <subfield code="t">Pancreatic enzymes --</subfield>
    <subfield code="t">Drugs used to dissolve gallstones --</subfield>
    <subfield code="t">Anorectal preparations --</subfield>
    <subfield code="g">15.</subfield>
    <subfield code="t">Nutrition --</subfield>
    <subfield code="g">79.</subfield>
    <subfield code="t">Vitamins --</subfield>
    <subfield code="t">General considerations --</subfield>
    <subfield code="t">Fat-soluble vitamins --</subfield>
    <subfield code="t">Water-soluble vitamins --</subfield>
    <subfield code="g">80.</subfield>
    <subfield code="t">Enteral and parenteral nutrition --</subfield>
    <subfield code="t">Enteral nutritional therapy --</subfield>
    <subfield code="t">Parenteral nutritional therapy --</subfield>
    <subfield code="t">Drugs for obesity --</subfield>
    <subfield code="t">Assessment of obesity-related health risk --</subfield>
    <subfield code="t">Overview of obesity treatment --</subfield>
    <subfield code="t">Weight-loss drugs approved for long-term use --</subfield>
    <subfield code="t">Miscellaneous appetite suppressants --</subfield>
    <subfield code="t">Investigational weight-loss drugs --</subfield>
    <subfield code="t">Calorie-saving foods</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2="0">
    <subfield code="g">[pt]. 16.</subfield>
    <subfield code="t">Chemotherapy of infectious diseases --</subfield>
    <subfield code="g">82.</subfield>
    <subfield code="t">Basic principles of antimicrobial therapy --</subfield>
    <subfield code="t">Selective toxicity --</subfield>
    <subfield code="t">Classification of antimicrobial drugs --</subfield>
    <subfield code="t">Acquired resistance to antimicrobial drugs --</subfield>
    <subfield code="t">Selection of antibiotics --</subfield>
    <subfield code="t">Host factors that modify drug choice, route of administration, or dosage --</subfield>
    <subfield code="t">Dosage size and duration of treatment --</subfield>
    <subfield code="t">Therapy with antibiotic combinations --</subfield>
    <subfield code="t">Prophylactic use of antimicrobial drugs --</subfield>
    <subfield code="t">Misuses of antimicrobial drugs --</subfield>
    <subfield code="t">Monitoring antimicrobial therapy --</subfield>
    <subfield code="g">83.</subfield>
    <subfield code="t">Drugs that weaken the bacterial cell wall 1 : penicillins --</subfield>
    <subfield code="t">Introduction to the penicillins --</subfield>
    <subfield code="t">Properties of individual penicillins --</subfield>
    <subfield code="g">84.</subfield>
    <subfield code="t">Drugs that weaken the bacterial cell wall 2 : cephalosporins, carbapenems, vancomycin, aztreonam, teicoplanin, and fosfomycin --</subfield>
    <subfield code="t">Cephalosporins --</subfield>
    <subfield code="t">Carbapenems --</subfield>
    <subfield code="t">Other inhibitors of cell wall synthesis --</subfield>
    <subfield code="g">85.</subfield>
    <subfield code="t">Bacteriostatic inhibitors of protein synthesis : tetracyclines, macrolides and others --</subfield>
    <subfield code="t">Tetracyclines --</subfield>
    <subfield code="t">Macrolides --</subfield>
    <subfield code="t">Other bacteriostatic inhibitors of protein synthesis --</subfield>
    <subfield code="g">86.</subfield>
    <subfield code="t">Aminoglycosides : bactericidal inhibitors of protein synthesis --</subfield>
    <subfield code="t">Basic pharmacology of the aminoglycosides --</subfield>
    <subfield code="g">87.</subfield>
    <subfield code="t">Sulfonamides and trimethoprim --</subfield>
    <subfield code="t">Sulfonamides --</subfield>
    <subfield code="t">Trimethoprim --</subfield>
    <subfield code="t">Trimethoprim/sulfamethoxazole --</subfield>
    <subfield code="g">88.</subfield>
    <subfield code="t">Drug therapy of urinary tract infections --</subfield>
    <subfield code="t">Organisms that cause urinary tract infections --</subfield>
    <subfield code="t">Specific urinary tract infections and their treatment --</subfield>
    <subfield code="t">Urinary tract antiseptics</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2="0">
    <subfield code="g">89.</subfield>
    <subfield code="t">Antimycobacterial agents : drugs for tuberculosis, leprosy, and mycobacterium avium complex infection --</subfield>
    <subfield code="t">Tuberculosis 1 : clinical considerations --</subfield>
    <subfield code="t">Tuberculosis 2 : pharmacology of individual antituberculosis drugs --</subfield>
    <subfield code="t">Drugs for leprosy (Hansen's disease) --</subfield>
    <subfield code="t">Drugs for mycobacterium avium complex infection --</subfield>
    <subfield code="g">90.</subfield>
    <subfield code="t">Miscellaneous antibacterial drugs : fluoroquinolones, metronidazole, daptomycin, rifampin, bacitracin, and polymyxins --</subfield>
    <subfield code="t">Fluoroquinolones --</subfield>
    <subfield code="t">Additional antibacterial drugs --</subfield>
    <subfield code="g">91.</subfield>
    <subfield code="t">Antifungal agents --</subfield>
    <subfield code="t">Drugs for systemic mycoses --</subfield>
    <subfield code="t">Drugs for superficial mycoses --</subfield>
    <subfield code="g">92.</subfield>
    <subfield code="t">Antiviral agents 1 : drugs for non-HIV viral infections --</subfield>
    <subfield code="t">Drugs for infection with herpes simplex viruses and varicella-zoster virus --</subfield>
    <subfield code="t">Drugs for cytomegalovirus infection --</subfield>
    <subfield code="t">Drugs for hepatitis --</subfield>
    <subfield code="t">Drugs for influenza --</subfield>
    <subfield code="t">Drugs for respiratory syncytial virus infection --</subfield>
    <subfield code="g">93.</subfield>
    <subfield code="t">Antiviral agents 2 : drugs for HIV infection and related opportunistic infections --</subfield>
    <subfield code="t">Pathophysiology --</subfield>
    <subfield code="t">Classification of antiretroviral drugs --</subfield>
    <subfield code="t">Nucleoside/nucleotide reverse transcriptase inhibitors --</subfield>
    <subfield code="t">Non-nucleoside reverse transcriptase inhibitors --</subfield>
    <subfield code="t">Protease inhibitors --</subfield>
    <subfield code="t">Enfuvirtide, an HIV fusion inhibitor --</subfield>
    <subfield code="t">Management of HIV infection --</subfield>
    <subfield code="t">Prophylaxis and treatment of opportunistic infections --</subfield>
    <subfield code="t">HIV vaccines --</subfield>
    <subfield code="t">Keeping current</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2="0">
    <subfield code="g">94.</subfield>
    <subfield code="t">Drug therapy of sexually transmitted diseases --</subfield>
    <subfield code="t">Chlamydia trachomatis infections --</subfield>
    <subfield code="t">Gonococcal infections --</subfield>
    <subfield code="t">Nongonococcal urethritis --</subfield>
    <subfield code="t">Pelvic inflammatory disease --</subfield>
    <subfield code="t">Acute epididymitis --</subfield>
    <subfield code="t">Syphilis --</subfield>
    <subfield code="t">Acquired immunodeficiency syndrome --</subfield>
    <subfield code="t">Chancroid --</subfield>
    <subfield code="t">Trichomoniasis --</subfield>
    <subfield code="t">Bacterial vaginosis --</subfield>
    <subfield code="t">Herpes simplex virus infections --</subfield>
    <subfield code="t">Genital and anal warts (condylomata acuminata) --</subfield>
    <subfield code="t">Proctitis --</subfield>
    <subfield code="g">95.</subfield>
    <subfield code="t">Antiseptics and disinfectants --</subfield>
    <subfield code="t">General considerations --</subfield>
    <subfield code="t">Properties of individual antiseptics and disinfectants --</subfield>
    <subfield code="t">Hand hygiene for healthcare workers --</subfield>
    <subfield code="g">[pt]. 17.</subfield>
    <subfield code="t">Chemotherapy of parasitic diseases --</subfield>
    <subfield code="g">96.</subfield>
    <subfield code="t">Anthelmintics --</subfield>
    <subfield code="t">Classification of parasitic worms --</subfield>
    <subfield code="t">Helminthic infestations --</subfield>
    <subfield code="t">Drugs of choice for helminthiasis --</subfield>
    <subfield code="g">97.</subfield>
    <subfield code="t">Antiprotozoal drugs 1: antimalarial agents --</subfield>
    <subfield code="t">Life cycle of the malaria parasite --</subfield>
    <subfield code="t">Types of malaria --</subfield>
    <subfield code="t">Principles of antimalarial therapy --</subfield>
    <subfield code="t">Pharmacology of the major antimalarial drugs --</subfield>
    <subfield code="g">98.</subfield>
    <subfield code="t">Antiprotozoal drugs 2 : miscellaneous agents --</subfield>
    <subfield code="t">Protozoal infections --</subfield>
    <subfield code="t">Drugs of choice for protozoal infections --</subfield>
    <subfield code="g">99.</subfield>
    <subfield code="t">Ectoparasiticides --</subfield>
    <subfield code="t">Ectoparasitic infestations --</subfield>
    <subfield code="t">Pharmacology of ectoparasiticides</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2="0">
    <subfield code="g">[pt]. 18.</subfield>
    <subfield code="t">Cancer chemotherapy --</subfield>
    <subfield code="g">100.</subfield>
    <subfield code="t">Basic principles of cancer chemotherapy --</subfield>
    <subfield code="t">What is cancer? --</subfield>
    <subfield code="t">The growth fraction and its relationship to chemotherapy --</subfield>
    <subfield code="t">Obstacles to successful chemotherapy --</subfield>
    <subfield code="t">Strategies for achieving maximum benefits from chemotherapy --</subfield>
    <subfield code="t">Major toxicities of chemotherapeutic drugs --</subfield>
    <subfield code="t">Making the decision to treat --</subfield>
    <subfield code="t">Looking ahead --</subfield>
    <subfield code="g">101.</subfield>
    <subfield code="t">Anticancer drugs 1: cytotoxic agents --</subfield>
    <subfield code="t">Introduction to the cytotoxic anticancer drugs --</subfield>
    <subfield code="t">Alkylating agents --</subfield>
    <subfield code="t">Platinum compounds --</subfield>
    <subfield code="t">Antimetabolites --</subfield>
    <subfield code="t">Antitumor antibiotics --</subfield>
    <subfield code="t">Mitotic inhibitors --</subfield>
    <subfield code="t">Mitotic inhibitors --</subfield>
    <subfield code="t">Topoisomerase inhibitors --</subfield>
    <subfield code="t">Miscellaneous cytotoxic drugs --</subfield>
    <subfield code="g">102.</subfield>
    <subfield code="t">Anticancer drugs 2 : hormonal agents, biologic response modifiers, and targeted drugs --</subfield>
    <subfield code="t">Glucocorticoids --</subfield>
    <subfield code="t">Drugs for prostate cancer --</subfield>
    <subfield code="t">Drugs for breast cancer --</subfield>
    <subfield code="t">Biologic response modifiers : immunostimulants --</subfield>
    <subfield code="t">Targeted drugs --</subfield>
    <subfield code="g">[pt]. 19.</subfield>
    <subfield code="t">Additional important drugs --</subfield>
    <subfield code="g">103.</subfield>
    <subfield code="t">Drugs for the eye --</subfield>
    <subfield code="t">Drugs for glaucoma --</subfield>
    <subfield code="t">Cycloplegics and mydriatics --</subfield>
    <subfield code="t">Drugs for allergic conjunctivitis --</subfield>
    <subfield code="t">Drugs for age-related macular degeneration --</subfield>
    <subfield code="t">Additional ophthalmic drugs</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2="0">
    <subfield code="g">104.</subfield>
    <subfield code="t">Drugs for the skin --</subfield>
    <subfield code="t">Anatomy of the skin --</subfield>
    <subfield code="t">Topical glucocorticoids --</subfield>
    <subfield code="t">Keratolytic agents --</subfield>
    <subfield code="t">Acne --</subfield>
    <subfield code="t">Sunscreens --</subfield>
    <subfield code="t">Psoriasis --</subfield>
    <subfield code="t">Other dermatologic drugs --</subfield>
    <subfield code="g">105.</subfield>
    <subfield code="t">Drugs for the ear --</subfield>
    <subfield code="t">Anatomy of the ear --</subfield>
    <subfield code="t">Otitis media and its management --</subfield>
    <subfield code="t">Otitis externa and its management --</subfield>
    <subfield code="g">106.</subfield>
    <subfield code="t">Miscellaneous noteworthy drugs --</subfield>
    <subfield code="t">Drugs for pulmonary arterial hypertension --</subfield>
    <subfield code="t">Drotrecogin Alfa (activated) for severe sepsis --</subfield>
    <subfield code="t">Drugs for neonatal respiratory distress syndrome --</subfield>
    <subfield code="t">Drugs for cystic fibrosis --</subfield>
    <subfield code="t">Drugs for sickle cell anemia --</subfield>
    <subfield code="t">Drugs for hyperuicemia caused by cancer chemotherapy --</subfield>
    <subfield code="t">Gamma-hydroxybutyrate for cataplexy in patients with narcolepsy --</subfield>
    <subfield code="t">Riluzole for amyotrophic lateral sclerosis --</subfield>
    <subfield code="g">[pt]. 20.</subfield>
    <subfield code="t">Alternative therapy --</subfield>
    <subfield code="g">107.</subfield>
    <subfield code="t">Herbal supplements --</subfield>
    <subfield code="t">Limited regulation : the Dietary Supplement Health and Education Act --</subfield>
    <subfield code="t">Adverse interactions with conventional drugs --</subfield>
    <subfield code="t">Oral formulations --</subfield>
    <subfield code="t">Standardization of herbal products --</subfield>
    <subfield code="t">Dosage --</subfield>
    <subfield code="t">Some commonly used medicinal herbs</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2="0">
    <subfield code="g">[pt]. 21.</subfield>
    <subfield code="t">Toxicology --</subfield>
    <subfield code="g">108.</subfield>
    <subfield code="t">Management of poisoning --</subfield>
    <subfield code="t">Fundamentals of treatment --</subfield>
    <subfield code="t">Drugs and procedures used to minimize poison absorption --</subfield>
    <subfield code="t">Drugs and procedures used for poison removal --</subfield>
    <subfield code="t">Specific antidotes --</subfield>
    <subfield code="t">Poison control centers --</subfield>
    <subfield code="g">109.</subfield>
    <subfield code="t">Potential weapons of biologic, radiologic, and chemical terrorism --</subfield>
    <subfield code="t">Bacteria and viruses --</subfield>
    <subfield code="t">Biotoxins --</subfield>
    <subfield code="t">Chemical weapons --</subfield>
    <subfield code="t">Radiologic weapons --</subfield>
    <subfield code="t">Appendixes --</subfield>
    <subfield code="g">A.</subfield>
    <subfield code="t">Adult immunization --</subfield>
    <subfield code="g">B.</subfield>
    <subfield code="t">Guide to gender-related drugs --</subfield>
    <subfield code="g">C.</subfield>
    <subfield code="t">Pronunciation of generic drug names --</subfield>
    <subfield code="g">D.</subfield>
    <subfield code="t">Weights and measures --</subfield>
    <subfield code="g">E.</subfield>
    <subfield code="t">Normal laboratory values --</subfield>
    <subfield code="g">F.</subfield>
    <subfield code="t">Commonly used abbreviations --</subfield>
    <subfield code="g">G.</subfield>
    <subfield code="t">Techniques of drug administration --</subfield>
    <subfield code="g">H.</subfield>
    <subfield code="t">Poison Control Centers in the United States --</subfield>
    <subfield code="g">I.</subfield>
    <subfield code="t">Canadian drug information --</subfield>
    <subfield code="g">J.</subfield>
    <subfield code="t">Major drug classes and their prototypes --</subfield>
    <subfield code="g">K.</subfield>
    <subfield code="t">Very new drugs and important new formulations of older drugs</subfield>
  </datafield>
  <datafield tag="538" ind1=" " ind2=" ">
    <subfield code="a">System requirements for Windows: Windows 98se, 2000, or XP ; Pentium II 400 MHz or faster processor ; at least 64 MB RAM recommended ; 10 MB free hard disk space ; 48X or faster CD-ROM drive ; 800 x 600 monitor with True Color</subfield>
  </datafield>
  <datafield tag="538" ind1=" " ind2=" ">
    <subfield code="a">System requirements for Macintosh: OS X or greater ; Power Macintosh ; at least 64 MB RAM recommended ; 1 GHz+ PowerPC G4 ; 10 MB free hard disk space ; 48X or faster CD-ROM drive ; 800 x 600 monitor with Millions of colors</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="0">
    <subfield code="a">Pharmacology</subfield>
    <subfield code="9">3844</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="0">
    <subfield code="a">Nursing</subfield>
    <subfield code="9">3976</subfield>
  </datafield>
  <datafield tag="650" ind1="1" ind2="2">
    <subfield code="a">Pharmacology</subfield>
    <subfield code="9">3844</subfield>
  </datafield>
  <datafield tag="650" ind1="1" ind2="2">
    <subfield code="a">Drug Therapy</subfield>
    <subfield code="9">3869</subfield>
  </datafield>
  <datafield tag="655" ind1=" " ind2="2">
    <subfield code="a">Nurses' Instruction</subfield>
    <subfield code="9">3887</subfield>
  </datafield>
  <datafield tag="942" ind1=" " ind2=" ">
    <subfield code="2">lcc</subfield>
    <subfield code="c">BK</subfield>
  </datafield>
  <datafield tag="999" ind1=" " ind2=" ">
    <subfield code="c">3488</subfield>
    <subfield code="d">3488</subfield>
  </datafield>
  <datafield tag="952" ind1=" " ind2=" ">
    <subfield code="0">0</subfield>
    <subfield code="1">0</subfield>
    <subfield code="2">lcc</subfield>
    <subfield code="4">0</subfield>
    <subfield code="6">QV0004 P45  02007</subfield>
    <subfield code="7">0</subfield>
    <subfield code="9">3705</subfield>
    <subfield code="a">KUNS</subfield>
    <subfield code="b">KUNS</subfield>
    <subfield code="c">GEN</subfield>
    <subfield code="d">2024-03-22</subfield>
    <subfield code="e">PURCHASE</subfield>
    <subfield code="o">QV4 P45 2007</subfield>
    <subfield code="p">2025-4378</subfield>
    <subfield code="r">2024-03-22</subfield>
    <subfield code="t">1</subfield>
    <subfield code="w">2024-03-22</subfield>
    <subfield code="y">BK</subfield>
    <subfield code="z">AVAILLABLE</subfield>
  </datafield>
</record>
